Skip to content

TriangleGet started

← Full study record

NCT03106779 · BASELINE

Baseline characteristics

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
157
group Id
BG001
value
76
group Id
BG002
value
233
units
Participants

groups

description
Participants randomized to asciminib 40mg BID
id
BG000
title
Asciminib
description
Participants randomized to bosutinib 500mg QD
id
BG001
title
Bosutinib
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
13.49
value
51.0
group Id
BG001
spread
13.95
value
51.0
group Id
BG002
spread
13.61
value
51.0
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
75
group Id
BG001
value
45
group Id
BG002
value
120
title
Female
measurements
group Id
BG000
value
82
group Id
BG001
value
31
group Id
BG002
value
113
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
118
group Id
BG001
value
56
group Id
BG002
value
174
title
White
categories
measurements
group Id
BG000
value
22
group Id
BG001
value
11
group Id
BG002
value
33
title
Asian
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
2
group Id
BG002
value
10
title
Black or African American
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
American Indian or Alaska Native
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
7
group Id
BG002
value
12
title
Other
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
0
group Id
BG002
value
3
title
Unknown
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants

population Description

Full Analysis Set (FAS): The FAS comprised of all randomized patients.

Complete source fields

denoms

counts
group Id
BG000
value
157
group Id
BG001
value
76
group Id
BG002
value
233
units
Participants

groups

description
Participants randomized to asciminib 40mg BID
id
BG000
title
Asciminib
description
Participants randomized to bosutinib 500mg QD
id
BG001
title
Bosutinib
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
13.49
value
51.0
group Id
BG001
spread
13.95
value
51.0
group Id
BG002
spread
13.61
value
51.0
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
75
group Id
BG001
value
45
group Id
BG002
value
120
title
Female
measurements
group Id
BG000
value
82
group Id
BG001
value
31
group Id
BG002
value
113
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
118
group Id
BG001
value
56
group Id
BG002
value
174
title
White
categories
measurements
group Id
BG000
value
22
group Id
BG001
value
11
group Id
BG002
value
33
title
Asian
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
2
group Id
BG002
value
10
title
Black or African American
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
American Indian or Alaska Native
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
7
group Id
BG002
value
12
title
Other
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
0
group Id
BG002
value
3
title
Unknown
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants

population Description

Full Analysis Set (FAS): The FAS comprised of all randomized patients.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice